Financial Performance Highlights

H1 FY27 Financial Results (Half-year ended September 30, 2026):

  • Revenue from operations: ₹48.90 crore (compared to ₹14.38 crore in H1 FY26, representing 240% YoY growth)
  • Total income: ₹48.96 crore
  • EBITDA: ₹7.68 crore
  • Profit before tax: ₹6.83 crore
  • Profit after tax: ₹5.08 crore

Business Overview:

Aptus Pharma Limited is a pharmaceutical company established in 2010 that has evolved from a local player to a nationally recognized company. The company focuses on pharmaceutical brand building, market development, and distribution of healthcare products.

Product Portfolio and Business Verticals:

  • Portfolio comprises more than 300 formulations across multiple therapeutic segments
  • Three business verticals:
  • Pharmaceutical formulation business (prescription-based therapies)
  • OTC and wellness vertical (consumer healthcare and complementary wellness categories)
  • Service vertical (international opportunities development)

Revenue Mix (H1 FY27):

  • Acute therapy: 44% of sales
  • Chronic and semi-chronic therapies: 20% of sales
  • Wellness and OTC products: 20% of sales
  • Sales of services: 16% of revenue

Operational Metrics:

  • Distribution network: 250+ distributors and sub-distributors
  • Retail availability: exceeding 45,000 outlets
  • Doctor relationships: trusted by more than 10,000 doctors
  • Medical representatives: 142 frontline staff on roll, plus 150+ professionals and 200+ sales representatives through distribution networks
  • Employee attrition ratio: below 5-6%

Balance Sheet Position (as of September 30, 2026):

  • Total assets: ₹54.55 crore
  • Inventory: ₹16.25 crore
  • Trade receivables: ₹28.64 crore

Strategic Priorities and Growth Plans

Three-Pillar Growth Strategy:

1. Manufacturing Expansion: Target development of approximately 20% product portfolio through own manufacturing capabilities by March 2028. Planned initial CAPEX of ₹35 crore, with ₹25 crore funded through preferential issue pending exchange approvals. The facility will be dedicated for self-consumption with remaining capacity for export to ROW countries.

2. Pan-India Distribution Network Expansion: Target 46% geographic coverage across India by March 2027, with long-term objective to establish pan-India footprint by 2029. Goal to achieve availability in every medical store across India's 8.5+ lakh pharmacies.

3. Global Expansion: Exploration of selected markets in Asia, Africa, and Latin America through gradual, opportunity-led approach.

Geographic Expansion Timeline:

  • Pre-listing: Presence in 2 states
  • March 2027 target: 46% geographic coverage of India
  • 2029 target: Pan-India presence

Management Commentary and Focus Areas

Management emphasized focus on:

  • Strengthening pharmaceutical formulation of acute and chronic therapy
  • Business development of OTC and wellness portfolio
  • Maintaining profitability and operating discipline
  • Working capital management (inventory levels, collection efficiency, credit discipline)
  • Regulatory compliance and responsible use of capital
  • Sales productivity improvement and distribution network development

Q&A Session Highlights

Growth Guidance: Management declined to provide specific forward-looking EBITDA, topline, or net profit margin guidance, stating they will disclose guidelines after compliance.

Manufacturing Plans: The company confirmed the manufacturing facility will be for self-consumption only (not CDMO), with initial CAPEX of ₹35 crore. Gross margins are expected to follow pharmaceutical industry norms.

USP and Competitive Advantage: Company highlighted diversified product portfolio across acute, chronic, OTC, and wellness therapies; experienced promoter team with roots in pharmaceuticals; and strong marketing team and distribution networks.

Future Focus: Core focus will be on lead brands, strengthening presence in tier 2 and tier 3 cities, and pan-India prescription generation.

Corrections Note

During the earnings call, the Managing Director inadvertently mentioned Total Assets as ₹44.55 crore instead of ₹54.55 crore, and year 2030 instead of 2029. These have been corrected in the transcript to reflect actual amounts and years.